rhp23 Antibody

What is rhp23 and why is it important in scientific research?

rhp23 is a functional homolog of human HHR23A and Saccharomyces cerevisiae RAD23, cloned from the fission yeast Schizosaccharomyces pombe. It plays critical roles in three major cellular processes: nucleotide excision repair (NER), cell cycle regulation, and protein ubiquitination pathways. The importance of rhp23 in research stems from its conserved functions across species, making it a valuable model for studying DNA repair mechanisms and their connections to cell cycle control. The rhp23 gene product demonstrates moderate sensitivity to UV light when mutated, but maintains wild-type resistance to gamma-rays and hydroxyurea, highlighting its specific role in UV-damage repair systems. Additionally, the rhp23::ura4 mutation causes a delay in the G2 phase of the cell cycle, which can be corrected by expression of rhp23, RAD23, or HHR23A cDNA, indicating functional conservation across species .

How specific are commercially available rhp23 antibodies and what cross-reactivity should researchers be aware of?

When working with rhp23 antibodies, specificity considerations are crucial for experimental design. Anti-Rad23 antibodies have been demonstrated to cross-react with Schizosaccharomyces pombe Rhp23 but not with human HHR23A, indicating partial cross-species reactivity. This specificity pattern was confirmed through multiple validation approaches: absence of the characteristic ~50 kDa band in extracts from rhp23::ura4 strains, appearance of a strong ~50 kDa band when rhp23 cDNA was overexpressed, detection of a slightly larger band when RAD23 cDNA was overexpressed, and no band detection when HHR23A cDNA was overexpressed. Researchers should verify antibody specificity through Western blot analysis in their specific experimental systems, particularly when working with tagged versions of the protein or in cross-species studies. When conducting immunoprecipitation experiments, appropriate controls should be included to account for potential cross-reactivity with structurally similar proteins containing ubiquitin-binding domains .

What are the recommended methods for detecting rhp23 in yeast cell lysates?

For optimal detection of rhp23 in yeast cell lysates, a comprehensive extraction protocol is recommended. Cells should be harvested in mid-log phase and lysed in buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% NP-40, 10% glycerol, 5 mM EDTA, 50 mM NaF, 1 mM Na₃VO₄, 5 mM PNPP, 15 mM MgCl₂, 15 mM EGTA, 1% Triton X-100, and 1 mM DTT. To prevent protein degradation, a mixture of protease inhibitors (1 mM PMSF, 20 μg/ml leupeptin, 40 μg/ml aprotinin, and 0.1 mM sodium vanadate) should be added immediately before cell disruption. Cell lysis should be performed by glass-bead agitation for 60 seconds using a homogenizer, with disruption efficiency confirmed under microscope observation. The process may need to be repeated 3-5 times for complete lysis. For immunoblot detection, 20-50 μg of protein should be resolved on SDS-PAGE gels and transferred to nitrocellulose membranes. Anti-Rad23 serum can be used as the primary antibody, with detection via enhanced chemiluminescence systems. Alpha-tubulin serves as an effective internal control for protein loading and normalization .

How can researchers effectively use rhp23 antibodies to study cell cycle-dependent protein localization?

To effectively study rhp23's cell cycle-dependent localization, researchers should employ a synchronized cell culture approach combined with immunofluorescence or cell fractionation techniques. Since nuclear levels of Rhp23 have been documented to decrease around S phase, synchronization at different cell cycle stages is essential for capturing this dynamic localization pattern. For fission yeast, synchronization can be achieved using hydroxyurea block (S phase), lactose gradient centrifugation, or temperature-sensitive cdc25 mutants (G2/M boundary). For immunofluorescence studies, formaldehyde fixation (3-4%) for 10 minutes followed by cell wall digestion with zymolyase is recommended. When analyzing results, researchers should quantify nuclear versus cytoplasmic signal intensities across at least 100 cells per condition and correlate localization patterns with cell cycle markers (such as DNA content by DAPI staining or specific cyclin levels). For biochemical validation, nuclear/cytoplasmic fractionation followed by immunoblotting can provide quantitative measurements of Rhp23 distribution changes throughout the cell cycle. Each experiment should include appropriate controls to account for antibody specificity and potential fixation artifacts that might affect apparent protein localization .

What protocols are most effective for studying rhp23 ubiquitination using rhp23 antibodies?

For studying rhp23 ubiquitination, a dual immunoprecipitation approach yields the most reliable results. First, prepare cell lysates under denaturing conditions (1% SDS, 5 mM EDTA, 50 mM Tris pH 7.5) with heating at 95°C for 5 minutes, followed by dilution in non-denaturing buffer (0.5% NP-40, 50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA) to final SDS concentration below 0.1%. This denaturing step disrupts non-covalent protein interactions while preserving ubiquitin conjugation. Include deubiquitinase inhibitors (5 mM N-ethylmaleimide and 20 μM PR-619) in all buffers. For detecting rhp23 ubiquitination, perform immunoprecipitation with rhp23 antibodies followed by immunoblotting with anti-ubiquitin antibodies. The reverse approach—immunoprecipitation with anti-ubiquitin antibodies followed by rhp23 detection—can provide complementary evidence. Since rhp23 is ubiquitinated at low levels under normal conditions, use of proteasome inhibitors (MG132, 10 μM for 4-6 hours) can enhance detection by preventing degradation of ubiquitinated species. For distinguishing between different ubiquitin chain types, include antibodies specific for K48-linked or K63-linked polyubiquitin chains in your analysis. When assessing the increased ubiquitination of other proteins upon rhp23 overexpression, employ gradient gels (4-15%) to resolve the broad range of ubiquitinated species effectively .

How can researchers use rhp23 antibodies to investigate its role in nucleotide excision repair?

To investigate rhp23's role in nucleotide excision repair (NER), researchers should employ a combination of UV damage induction and repair kinetics assessment using rhp23 antibodies. Begin by exposing cells to controlled UV-C doses (10-100 J/m²) and collecting samples at defined time points post-irradiation (0, 1, 2, 4, and 6 hours). For immunofluorescence approaches, co-staining with antibodies against other NER factors (such as XPC in mammalian cells or its homolog in yeast) can reveal recruitment dynamics to damage sites. For biochemical approaches, chromatin fractionation followed by immunoblotting with rhp23 antibodies can quantify damage-dependent chromatin association. To directly visualize rhp23 recruitment to DNA damage sites, employ local UV irradiation through micropore filters followed by immunodetection of both DNA damage markers (such as CPD or 6-4PP antibodies) and rhp23. For functional assessment, complement these localization studies with DNA repair assays such as unscheduled DNA synthesis or host cell reactivation assays in wild-type versus rhp23-mutant backgrounds. When analyzing data, account for cell cycle position, as S-phase cells may show altered rhp23 nuclear levels independent of DNA damage responses. Include appropriate controls such as NER-deficient cells (e.g., XPA-mutants) to benchmark repair efficiency measurements .

What are common issues when detecting rhp23 in immunoblotting experiments and how can they be resolved?

When encountering difficulties detecting rhp23 in immunoblotting experiments, several technical issues may be responsible. Insufficient protein extraction is a common problem, particularly given rhp23's nuclear localization. To address this, ensure complete cell lysis by incorporating additional mechanical disruption cycles and verify extraction efficiency with microscopy. For fission yeast, include zymolyase pre-treatment (1 mg/ml for 30 minutes at 30°C) to weaken cell walls before mechanical disruption. If signal appears weak despite confirmed extraction, modify transfer conditions by extending transfer time for high molecular weight proteins or using PVDF membranes instead of nitrocellulose for better protein retention. When working with anti-Rad23 antibodies that cross-react with rhp23, optimal blocking conditions typically include 5% non-fat dry milk in TBS-T for 1 hour at room temperature. If background remains high, try alternative blocking agents such as 5% BSA or commercial blocking reagents. Since rhp23 levels decrease during S phase, asynchronous cultures may show variable expression; synchronize cells if consistent detection is required. Finally, use a loading control such as α-tubulin that shows stable expression across conditions for accurate normalization. If all optimization fails, consider generating epitope-tagged rhp23 constructs and detecting with highly specific tag antibodies as an alternative approach .

How should researchers interpret conflicting data between rhp23 antibody staining and functional assays?

When facing discrepancies between rhp23 antibody staining patterns and functional assay results, a systematic analytical approach is essential. First, examine antibody specificity by conducting validation experiments including: western blot analysis comparing wild-type and rhp23-deletion strains, peptide competition assays to confirm epitope specificity, and testing multiple antibodies targeting different regions of rhp23 if available. For functional discrepancies, consider that rhp23 has multiple cellular roles (NER, cell cycle regulation, and ubiquitination pathways), so apparent contradictions may reflect context-dependent functions rather than technical artifacts. Additionally, evaluate whether post-translational modifications might affect antibody recognition without altering function (or vice versa); phosphorylation-specific or ubiquitination-specific antibodies can help resolve such cases. Cell cycle position significantly impacts both rhp23 localization and function, with nuclear levels decreasing around S phase, so asynchronous populations may produce seemingly inconsistent results. Finally, consider genetic redundancy—expression of related proteins like Rhp23/RAD23/HHR23A can compensate for certain functions in particular contexts, potentially explaining functional rescue despite aberrant staining patterns. Document all experimental conditions meticulously, as buffer components, fixation methods, and environmental stressors can all influence both antibody accessibility and protein functionality .

What controls are essential when using rhp23 antibodies in co-localization studies with other proteins?

When conducting co-localization studies with rhp23 antibodies and other proteins, rigorous controls are essential for valid interpretation. Single-antibody controls must be performed first to establish baseline staining patterns and detect any channel bleed-through, particularly important when studying nuclear proteins like rhp23 where signal density is high. Secondary-only controls (omitting primary antibodies) are critical to identify non-specific binding of secondary antibodies. When dual-species primary antibodies are used, confirming that secondary antibodies don't cross-react with the wrong primary is essential. For quantitative co-localization analysis, include both positive controls (proteins known to interact with rhp23, such as ubiquitin) and negative controls (proteins occupying similar cellular compartments but not interacting with rhp23). When studying disease-relevant co-localization (as with HR23B in neurodegenerative conditions), always compare pathological samples with age-matched controls processed identically. If studying rhp23's co-localization with ubiquitinated substrates, include proteasome inhibitors (MG132) and non-treated conditions to distinguish between transient and stable interactions. For super-resolution microscopy approaches, additional controls addressing sample drift and chromatic aberration are needed for accurate co-localization claims. Finally, complement imaging with biochemical interaction methods (co-immunoprecipitation or proximity ligation assays) to validate true molecular associations versus coincidental spatial proximity .

How can researchers use rhp23 antibodies to investigate its role in neurodegenerative disease models?

To investigate rhp23's role in neurodegenerative disease models, researchers should employ a multifaceted approach targeting its human homolog HR23B. HR23B inclusions have been identified in several neurodegenerative disorders including frontotemporal dementia (FTD), Huntington's disease, spinocerebellar ataxias, and Parkinson's disease. Begin with immunohistochemistry on post-mortem brain sections using standardized antigen retrieval methods (0.01M sodium citrate, pH 6.0, pressure cooker treatment) followed by endogenous peroxidase blocking (0.6% H₂O₂ with 1.25% sodium azide in PBS). For co-localization studies, perform double immunofluorescence staining combining HR23B antibodies with disease-specific markers such as TDP-43, poly-GA dipeptides (in C9ORF72-linked cases), or p62. To reduce background autofluorescence in brain tissue, include a 10-minute Sudan Black treatment (0.1g in 100ml 70% ethanol) after secondary antibody incubation. Quantify co-localization percentages across different brain regions, as HR23B shows variable co-localization patterns (e.g., higher in hippocampal dentate gyrus than frontal cortex in C9ORF72 cases). For functional studies, analyze expression patterns of HR23B binding partners involved in nucleotide excision repair (XPC), the ubiquitin-proteasome system (20S proteasome), and ER-associated degradation (NGly1/PNGase) to identify pathway disruptions. Complement tissue studies with cellular models expressing disease-associated mutations to assess HR23B recruitment to aggregates and potential functional sequestration from normal roles in DNA repair and protein degradation pathways .

What methodologies are most effective for studying interactions between rhp23 and the proteasome using rhp23 antibodies?

For studying interactions between rhp23 and the proteasome, a multi-method approach yields the most comprehensive results. Begin with co-immunoprecipitation experiments using rhp23 antibodies under native conditions (buffer: 50mM Tris-HCl pH 7.5, 150mM NaCl, 1mM EDTA, 0.5% NP-40, 10% glycerol) supplemented with ATP (2mM) to preserve proteasome integrity. Immunoblot for proteasome subunits (19S regulatory and 20S core) to detect physical association. For confirming specificity, perform reciprocal immunoprecipitation with antibodies against proteasome components. To visualize interactions in situ, use proximity ligation assays (PLA) combining rhp23 and proteasome subunit antibodies, which generate fluorescent signals only when proteins are within 40nm proximity. For functional assessment of rhp23-proteasome interactions, compare proteasome activity (using fluorogenic peptide substrates) in wild-type versus rhp23-depleted conditions. Additionally, analyze changes in global ubiquitination patterns when rhp23 is overexpressed, as increased ubiquitination of other proteins has been documented. When interpreting results, consider that rhp23's UbL domain mediates proteasome interaction while its UBA domains bind ubiquitinated substrates, positioning it as a shuttle factor. To test this shuttle function, design experiments with rhp23 domain mutants (UbL or UBA) to determine which interactions are disrupted. Finally, complement these approaches with in vitro binding assays using purified components to establish direct versus indirect interactions and potential regulatory mechanisms .

How can researchers design experiments to distinguish between rhp23's roles in DNA repair versus ubiquitin-proteasome pathways?

To experimentally distinguish between rhp23's roles in DNA repair versus ubiquitin-proteasome pathways, researchers should implement a strategic approach using specialized mutants and assay systems. Begin by generating domain-specific mutants: target the ubiquitin-like (UbL) domain to disrupt proteasome interactions while preserving DNA repair functions, and separately modify the ubiquitin-associated (UBA) domains to affect ubiquitinated substrate binding. For DNA repair function assessment, measure UV sensitivity using survival assays after UV exposure at varying doses (10-100 J/m²), comparing wild-type, complete rhp23 deletion, and domain-specific mutants. Complement with direct DNA repair measurements using unscheduled DNA synthesis or removal kinetics of UV-induced DNA lesions (CPDs and 6-4PPs). For proteasome pathway function, quantify global protein ubiquitination levels in the different strains before and after proteasome inhibition (MG132 treatment). Additionally, measure degradation kinetics of known proteasome substrates using cycloheximide chase assays. To establish cellular pathway connections, perform epistasis analysis by creating double mutants with known NER factors (rhp41/XPC equivalent) or proteasome components (rpn10). Most critically, design rescue experiments testing whether human HHR23A or S. cerevisiae RAD23 can complement specific defects in your mutants—these homologs have been shown to restore UV resistance in rhp23 mutants but may differentially complement proteasome-related functions. Finally, analyze cell cycle progression in your mutants, as rhp23::ura4 mutation causes G2 phase delay, potentially linking cell cycle regulation to one or both pathways .

What are the best methodologies for comparative studies of rhp23 and its homologs across species using antibodies?

For rigorous comparative studies of rhp23 and its homologs across species, researchers should implement a systematic antibody-based approach addressing specificity challenges and functional conservation. Begin by establishing antibody cross-reactivity profiles for each species variant through western blotting of recombinant proteins and knockout/mutant cell extracts. Anti-Rad23 antibodies have been demonstrated to cross-react with S. pombe rhp23 but not with human HHR23A, highlighting the need for careful validation. When antibodies show limited cross-reactivity, consider developing a panel of species-specific antibodies targeting conserved epitopes, or alternatively, use epitope tagging (FLAG, HA, etc.) with identical tags across species to enable standardized detection. For comparative immunolocalization studies, standardize fixation protocols across cell types, as differences in cell wall composition (particularly relevant in yeast versus mammalian cells) can affect antibody accessibility. When comparing functions across species, design parallel experiments examining conserved processes: UV sensitivity assays, cell cycle progression analysis, and proteasome interaction studies. For quantitative comparisons, develop species-normalized assays such as comparing the percentage reduction in nuclear localization during S phase rather than absolute protein levels. To address evolutionary divergence, supplement antibody-based approaches with genetic complementation experiments testing whether human HR23A/B can rescue phenotypes in rhp23-deficient S. pombe, and conversely, whether rhp23 expression can complement defects in HR23A/B-deficient human cells. Finally, for publications, present comparative data in standardized tables showing conservation and divergence in localization patterns, interaction partners, and functional rescue capabilities across species .

How can researchers effectively use rhp23 antibodies to study protein degradation pathways across model organisms?

To effectively study protein degradation pathways across model organisms using rhp23 antibodies, researchers should adopt a comprehensive comparative approach focusing on both conserved and species-specific mechanisms. Begin by establishing baseline ubiquitination profiles in each organism under normal conditions and after proteasome inhibition (MG132 for mammalian cells; temperature-sensitive proteasome mutants for yeast), using anti-ubiquitin antibodies alongside rhp23/homolog detection. Since rhp23 overexpression in S. pombe increases ubiquitination of other proteins, develop parallel overexpression systems across species to determine conservation of this regulatory function. For analysis of specific degradation pathways, focus on ER-associated degradation (ERAD) by examining rhp23's interaction with NGly1/PNGase across species, using co-immunoprecipitation with rhp23 antibodies followed by NGly1/PNGase detection. Design comparative stress response experiments exposing cells to protein misfolding stressors (heat shock, tunicamycin, or DTT) and tracking rhp23/homolog redistribution using immunofluorescence. For quantitative substrate degradation assays, establish reporter systems with model substrates (β-galactosidase fusion proteins containing degradation signals) in each organism and measure degradation kinetics when rhp23/homologs are present versus depleted. When interpreting cross-species data, account for differences in proteasome composition and regulation between organisms. Finally, create a detailed interaction map comparing rhp23/homolog binding partners across species using immunoprecipitation-mass spectrometry approaches, particularly focusing on species-specific interactors that might explain functional differences in protein quality control systems between yeasts and higher eukaryotes .